Thomas N Darling

Summary

Affiliation: Uniformed Services University of the Health Sciences
Country: USA

Publications

  1. pmc Simultaneous deficiency in CD28 and STAT6 results in chronic ectoparasite-induced inflammatory skin disease
    Qian Liu
    Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    Infect Immun 72:3706-15. 2004
  2. ncbi request reprint Hamartomas and tubers from defects in hamartin-tuberin
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Am Acad Dermatol 51:S9-11. 2004
  3. ncbi request reprint Hitting the mark in hamartoma syndromes
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Adv Dermatol 22:181-200. 2006
  4. pmc Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas
    Shaowei Li
    Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 4712, USA
    Proc Natl Acad Sci U S A 105:3539-44. 2008
  5. pmc Lymphangioleiomyomatosis and TSC2-/- cells
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Lymphat Res Biol 8:59-69. 2010
  6. pmc Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis
    Shaowei Li
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Nat Commun 2:235. 2011
  7. pmc Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences
    Diane Seibert
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Ann Intern Med 154:806-13, W-294. 2011
  8. pmc Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2
    Yoshihiko Ikeda
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1590, USA
    Am J Physiol Lung Cell Mol Physiol 300:L64-72. 2011
  9. ncbi request reprint TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis
    Gustavo Pacheco-Rodriguez
    Pulmonary Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892 1434, USA
    Cancer Res 67:10573-81. 2007
  10. pmc Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis
    Xiong Cai
    Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Respir Crit Care Med 182:1410-8. 2010

Research Grants

Collaborators

Detail Information

Publications21

  1. pmc Simultaneous deficiency in CD28 and STAT6 results in chronic ectoparasite-induced inflammatory skin disease
    Qian Liu
    Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Rd, Bethesda, MD 20814, USA
    Infect Immun 72:3706-15. 2004
    ..These findings suggest that ubiquitous ectoparasites, which are generally considered to be commensal, may contribute to disease when specific molecules required for an effective Th2 response are blocked...
  2. ncbi request reprint Hamartomas and tubers from defects in hamartin-tuberin
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Am Acad Dermatol 51:S9-11. 2004
  3. ncbi request reprint Hitting the mark in hamartoma syndromes
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Adv Dermatol 22:181-200. 2006
    ..It is hoped that the debilitating effects of these syndromes soon will be alleviated or even reversed though targeted therapies...
  4. pmc Mesenchymal-epithelial interactions involving epiregulin in tuberous sclerosis complex hamartomas
    Shaowei Li
    Department of Dermatology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814 4712, USA
    Proc Natl Acad Sci U S A 105:3539-44. 2008
    ..These results suggest that hamartomatous TSC skin tumors are induced by paracrine factors released by two-hit cells in the dermis and that proliferation with mTOR activation of the overlying epidermis is an effect of epiregulin...
  5. pmc Lymphangioleiomyomatosis and TSC2-/- cells
    Thomas N Darling
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Lymphat Res Biol 8:59-69. 2010
    ..Further improvements in the ability to reliably grow well-characterized TSC2(-/-) cells from human tumors are critical to developing in vitro and in vivo model systems for studies of LAM pathogenesis and treatment...
  6. pmc Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis
    Shaowei Li
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    Nat Commun 2:235. 2011
    ..These studies indicate that TSC2-null cells are the inciting cells for TSC skin hamartomas, and suggest that studies on hamartomas will provide insights into tissue morphogenesis and regeneration...
  7. pmc Recognition of tuberous sclerosis in adult women: delayed presentation with life-threatening consequences
    Diane Seibert
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    Ann Intern Med 154:806-13, W-294. 2011
    ....
  8. pmc Erythropoietin-driven proliferation of cells with mutations in the tumor suppressor gene TSC2
    Yoshihiko Ikeda
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 1590, USA
    Am J Physiol Lung Cell Mol Physiol 300:L64-72. 2011
    ..Although the high red cell mass of LAM patients could be related to advanced disease, we propose that EPO, synthesized in response to episodic hypoxia, may increase disease progression by enhancing the proliferation of LAM cells...
  9. ncbi request reprint TSC2 loss in lymphangioleiomyomatosis cells correlated with expression of CD44v6, a molecular determinant of metastasis
    Gustavo Pacheco-Rodriguez
    Pulmonary Critical Care Medicine Branch, National Heart, Lung, and Blood Institute, NIH, Bethesda, MD 20892 1434, USA
    Cancer Res 67:10573-81. 2007
    ..00003) and may be a biomarker for LAM. The cell surface receptor CD44 and its splice variant CD44v6 may contribute to the metastatic potential of LAM cells...
  10. pmc Phenotypic characterization of disseminated cells with TSC2 loss of heterozygosity in patients with lymphangioleiomyomatosis
    Xiong Cai
    Cardiovascular and Pulmonary Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
    Am J Respir Crit Care Med 182:1410-8. 2010
    ....
  11. doi request reprint Antibody microarrays: analysis of cystic fibrosis
    Catherine E Jozwik
    Department of Anatomy, Physiology and Genetics, Uniformed Services University School of Medicine, Bethesda, MD, USA
    Methods Mol Biol 823:179-200. 2012
    ..We describe here a workflow that begins with patient-derived bronchial brush biopsies and progresses to analysis of serum and plasma from patients on antibody microarrays...
  12. pmc Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA
    Marjorie J Lindhurst
    The National Human Genome Research Institute, US National Institutes of Health, Bethesda, Maryland, USA
    Nat Genet 44:928-33. 2012
    ..Our findings characterize a distinct overgrowth syndrome, biochemically demonstrate activation of PI3K signaling and thereby identify a rational therapeutic target...
  13. pmc Acral lesions in tuberous sclerosis complex: insights into pathogenesis
    Capt Shelley L Aldrich
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Am Acad Dermatol 63:244-51. 2010
    ..Patients with tuberous sclerosis complex (TSC) are predisposed to developing ungual fibromas and other acral lesions...
  14. pmc MCP-1 overexpressed in tuberous sclerosis lesions acts as a paracrine factor for tumor development
    Shaowei Li
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Exp Med 202:617-24. 2005
    ..Together these findings suggest that MCP-1 is an important paracrine factor for TSC tumorigenesis and may be a new therapeutic target...
  15. doi request reprint Physical, psychological and ethical issues in caring for individuals with genetic skin disease
    Diane C Seibert
    Family Nurse Practitioner Program, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
    J Nurs Scholarsh 45:89-95. 2013
    ..The purpose of this article, therefore, is to increase nurses' awareness and understanding of some of the physical, psychological, social, and ethical issues facing patients with inherited skin disorders...
  16. doi request reprint Sex-specific lung diseases: effect of oestrogen on cultured cells and in animal models
    Bosung Shim
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA
    Eur Respir Rev 22:302-11. 2013
    ..Anti-oestrogen treatments that target key events of oestrogen synthesis or signalling, such as aromatase activity, oestrogen receptors and signalling pathways, may offer additional opportunities for clinical trials. ..
  17. pmc Lymphatic involvement in lymphangioleiomyomatosis
    Connie G Glasgow
    Translational Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bldg 10, Rm 6D03 MSC 1590, Bethesda, MD 20892 1590, USA
    Ann N Y Acad Sci 1131:206-14. 2008
    ..Consistent with extensive lymphatic involvement in LAM, the serum concentration of VEGF-D, a lymphangiogenic factor, is higher in LAM patients than in healthy volunteers...
  18. pmc Progressive overgrowth of the cerebriform connective tissue nevus in patients with Proteus syndrome
    Thomas M Beachkofsky
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Am Acad Dermatol 63:799-804. 2010
    ..Proteus syndrome is a rare overgrowth disorder that almost always affects the skin...
  19. pmc A mosaic activating mutation in AKT1 associated with the Proteus syndrome
    Marjorie J Lindhurst
    National Human Genome Research Institute, Bethesda, Maryland, USA
    N Engl J Med 365:611-9. 2011
    ..The Proteus syndrome is characterized by the overgrowth of skin, connective tissue, brain, and other tissues. It has been hypothesized that the syndrome is caused by somatic mosaicism for a mutation that is lethal in the nonmosaic state...
  20. ncbi request reprint Evolution of skin lesions in Proteus syndrome
    James V Twede
    Department of Dermatology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814, USA
    J Am Acad Dermatol 52:834-8. 2005
    ..Proteus syndrome is a rare overgrowth disorder that is generally progressive, but the natural history of the skin lesions is not known...
  21. ncbi request reprint Rapidly growing collagenomas in multiple endocrine neoplasia type I
    Yang Xia
    Department of Dermatology at National Capital Consortium, Walter Reed Army Medical Center, Washington, DC, USA
    J Am Acad Dermatol 56:877-80. 2007
    ..Rapid growth of protuberant collagenomas appears to be unusual in MEN-I, but we suggest that MEN-I be considered in patients with apparent eruptive collagenoma...

Research Grants5

  1. Tumorigenesis in Tuberous Sclerosis
    Thomas Darling; Fiscal Year: 2007
    ..The elucidation of growth factors involved in these processes will provide molecular targets for the design of new therapies. ..
  2. Novel in vitro and xenograft models to study treatments for tuberous sclerosis
    Thomas Darling; Fiscal Year: 2007
    ..Finally, these in vitro and xenograft models can be used to investigate TSC tumor microenvironment and drug mechanisms of action, increasing our understanding of how these hamartomatous tumors form and respond to treatment. ..